Index

acceptance and commitment therapy (ACT) 597–8
social anxiety 598–601
acceptance therapy 590–2
adolescents see children and adolescents
β-adrenergic antagonists 532
adrenocorticotropic hormone (ACTH) 455
affiliative psychology 40–1
emotion regulation 42–3
shame 41–2
affirmation 276
age of onset of SAD 182
agoraphobia 204
alcohol use 551
alcohol use disorder 212
alprazolam 483, 524, 528, 531
Alzheimer’s disease 161
ambivalence 277
amygdala 69, 79, 91
hyperreactivity 395–7
response before and after SAD treatment 398–9
anticonvulsants 532–3
antisocial personality disorder (ASPD) 210–12
Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV) 282–3, 308–9
anxiety-related behaviors 357
anxiety sensitivity 97, 500
applied relaxation (AR) 479, 480–1
Internet-based 574
Approach-Avoidance Task (AAT) 348–9, 414
archetypal disposition 25
arginine vasopressin (AVP) 74–5
Asperger’s Disorder (AD) 378
atenolol 527, 534
attachment processes 187–8
attachment theory 187–8
attention bias modification (ABM) programs 420
attention deficit hyperactivity disorder (ADHD) 135
attention training (ATT) 516
attentional deployment 418
attractiveness 33–4, 40–1
atypical antipsychotics 533
atypical depression 206, 521
audacious trust 165
automatic thoughts, positive and negative 442
avoidance 167
avoidance of social interactions 446
avoidant personality disorder (APD/AVPD) 111, 125, 208–10, 249–50
clinical interviews 271, 279
basal hyperarousal 94
behavioral approach system (BAS) 14–15
behavioral deviations 360
  evolution of SAD and behavioral biases 344–6
model of cognition and behaviour in SAD 355–9
models of biased processing 346–8
social devaluation behaviors 348
  anxious behavior 354–5
  avoidance during social interactions 348–9
  facial mimicry 350–1
  interpersonal distance and personal space 349–50
  social skills and social behavior 352–4
behavioral inhibition (BI) 59–60, 92–3, 133
  assessment questionnaire 144–6
  association with anxiety disorders 139–40
  depression 140
  family studies 136
  prospective studies 136–9
  symptoms other than social anxiety 139
children and adolescents 181, 194
  cultural considerations 140–1
  definition 133–4
  future directions 147–8
  genetic underpinnings 135–6
  neurobiological underpinnings 134–5
  neuroimaging studies 134–5
  physiologic reactivity 134
  preventive intervention 142–7
  risk factor for SAD 141–2
behavioral inhibition system (BIS) 14–15
benzodiazepines 531–2
beta-blockers 532
bipolar disorder 208
bivalent fear of evaluation model 434
blood oxygen-level-dependent (BOLD) responses 395
blushing 57, 91–2, 96–7
brain-derived neurotrophic factor (BDNF) 401
Brief Intervention for Socially Anxious Drinkers (BISAD) 559
Brief Social Phobia Scale (BSPS) 285–6
brofaromine 524, 534
bromazepam 524, 531–2
buspirone 527, 532, 534, 535
cannabidiol 533
cannabis use 213–14, 550
care giving 28
care seeking/receiving 28
cautious trust 165
children and adolescents 181, 194
developmental psychology
  developmental psychopathology 184–5
  developmental theory 182–4
  implications for research and practice 194–5
pathways to SAD 185
  attachment processes 187–8
  behavioral inhibition (BI) 185–7
  emotion regulation 188–91
  parenting practices 191–2
  peer relationships 192–4
  pharmacotherapy 537
  social anxiety disorder 181–2
circumplex models 162–3
  interpersonal circumplex theory 119–21
citalopram 526, 529
Clark–Wells model of SAD 8–9, 347
Clinical Global Impression (CGI) Change Scale 522
clinical interviews for SAD 271–2
  conceptualization 272–4
  conducting the interview approaches 275
  behaviors to consider during interview 277–8
  cultural and developmental considerations 280–1
  differential diagnosis 279–80
  environment 274
  motivational interviewing 275–7
  subtypes and pervasiveness of SAD 278–9
recommendations 286–7
structured and semi-structured interviews 282
diagnostic interviews 282–4
symptom severity assessment 284–6
Index

clonazepam 483, 524, 528, 531–2
cocaine use 551
cognitive behavioral models of SAD 3
Clarke and Wells (1995) cognitive model 3
dysfunctional processes 4–5
comparison between models 7–9
future directions 20
other models
  evolutionary/psychobiological models 16–17
  interpersonal model of SAD 15–16
  Reinforcement Sensitivity Theory (RST) 13–15
  self-presentation model of SAD 12–13
overview of models
discrepancy as the key 18
etiology and developmental perspectives 17–18
social anxiety as adaptive and normative 18–19
SAD as intrapersonal and interpersonal disorder 19
Rapee and Heimberg (1997)
  cognitive–behavioral model 5
dysfunctional processes 5–7
recent models
Hofmann (2007) cognitive factors that maintain SAD 9–10
Moscovitch (2009) proposed core fear in SAD 10–11
importance of the self in understanding SAD 11–12
cognitive behavioral therapy (CBT) for SAD 477, 490–1, 498, 516–17
see also treatment for SAD
adaptations of treatment comorbidities 513
diverse populations 511–13
group versus individual 511
medication 513–14
assessment 498–501
cognitive strategies 502
  behavioral experiments 504
  challenging anxiety-provoking thoughts 502–4
  core beliefs 505–6
  new data collection 504–5
compared with other therapies
  interpersonal psychotherapy (IPT) 482–3
  mindfulness-based therapies 481–2
comparisons and combinations with pharmacotherapy 483–4
diversity considerations 233–7
emerging treatments 515
cognitive bias training 516
imagery rescripting 516
virtual reality exposure therapy (VRET) 515
exposure 477–9
exposure-based strategies 506
guidelines 507–8
hierarchy development 507
rationale for exposure 506
types of exposure 509
exposure combined with cognitive restructuring 478–9
exposure combined with nontraditional pharmacotherapy 484–5
factors affecting outcome
comorbidity 486–7
homework compliance
outcome expectancy 487
subtype of SAD 486
supplementary treatment components 487–8
treatment modality 487
further study issues
nonresponders to treatment 489–90
understudied populations 488–9
neuroimaging findings 485
psychoeducation 501–2
relapse prevention 514–15
relaxation techniques 480–1, 511
single case studies 237–8
social skills training (SST) 479–80, 509–10
video feedback 510
cognitive bias modification (CBM) 326
cognitive biases 323–4
future research 335–6
implicit associations 333–4
interpretations and judgment 324–6
post-event processing (PEP) and memory 331–3
cognitive biases (Continued)
selective attention bias 326–7
conscious 329–31
unconscious 327–8
cognitive change 418
cognitive preparation 334
adaptations
combining with medications 513–14
comorbidities 513
diverse populations 511–13
group versus individual format 511
assessment 498–501
augmentation strategies
applied relaxation 511
social skills training 509–10
video feedback 510
cognitive strategies 502
behavioral experiments 504
challenging anxiety-provoking thoughts 502–4
core beliefs 505–6
new data collection 504–5
combination of nontraditional pharmacotherapy and exposure 484–5
comparison and combination with pharmacotherapy 483–4
comparison with other psychotherapies
interpersonal psychotherapy (IPT) 482–3
mindfulness-based therapies 481–2
emerging treatments and future directions 515
cognitive bias training 516
imagery rescripting 516
virtual reality exposure therapy (VRET) 515
exposure 477–8
exposure and cognitive restructuring
combined 478–9
exposure-based strategies 506
exposure guidelines 507–8
exposure hierarchy 507
exposure types 509
rationale 506
factors affecting outcome
comorbidities 486–7
expectancy 487
homework compliance 488
subtypes 486
supplementary treatment components 487–8
treatment modality 487
further study
treatment nonresponders 489–90
understudied populations 488–9
neuroimaging findings 485
psychoeducation 501–2
relapse prevention 514–15
relaxation techniques 480–1
session protocol 499
social skills training 479–80
combined cognitive bias hypothesis 358
common method variance (CMV) 303, 307–8
communicative behaviours 357
comorbidities with SAD 201–2, 215
anxiety disorders
generalized anxiety disorder (GAD) 202–3
obsessive–compulsive disorder (OCD) 203–4
panic disorder with/without agoraphobia 204
posttraumatic stress disorder (PTSD) 205
CBT outcomes 486–7, 513
mood disorders
bipolar disorder 208
dysthymic disorder 207–8
major depressive disorder 205–7
personality disorders
avoidant personality disorder (APD) 208–10, 249–50
conduct disorder (CD) and antisocial personality disorder (ASPD) 210–12
substance use disorders 212
alcohol 212
cannabis 213–14
other illicit substances 214–15
tobacco 213
compassion 44–5
self-compassion 45–6
competition and evolutionary change 31–2
resource competition, group living and social hierarchies 33
<table>
<thead>
<tr>
<th>Index</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>competitive behavior 28</td>
<td></td>
</tr>
<tr>
<td>complementarity 162</td>
<td></td>
</tr>
<tr>
<td>conditioned response (CR) 456</td>
<td></td>
</tr>
<tr>
<td>conditioned stimulus (CS) 456</td>
<td></td>
</tr>
<tr>
<td>conduct disorder (CD) 210–12</td>
<td></td>
</tr>
<tr>
<td>confirmatory factor analysis (CFA) 116, 302</td>
<td></td>
</tr>
<tr>
<td>conflicts 29, 34</td>
<td></td>
</tr>
<tr>
<td>construct validity 300</td>
<td></td>
</tr>
<tr>
<td>contextual behavioral science 596–7</td>
<td></td>
</tr>
<tr>
<td>convergent validity 302</td>
<td></td>
</tr>
<tr>
<td>cooperative behavior 28</td>
<td></td>
</tr>
<tr>
<td>corticotrophin-releasing hormone (CRH) 59–60, 135, 136</td>
<td></td>
</tr>
<tr>
<td>cortisol 393</td>
<td></td>
</tr>
<tr>
<td>critical parenting style 191</td>
<td></td>
</tr>
<tr>
<td>cultural aspects of SAD 101–4</td>
<td></td>
</tr>
<tr>
<td>behavioral inhibition (BI) 140–1</td>
<td></td>
</tr>
<tr>
<td>Curse of the Self</td>
<td></td>
</tr>
<tr>
<td>D-cycloserine (DCS) 392–3, 484–5</td>
<td></td>
</tr>
<tr>
<td>depression</td>
<td></td>
</tr>
<tr>
<td>atypical depression 206, 521</td>
<td></td>
</tr>
<tr>
<td>behavioral inhibition (BI) 140</td>
<td></td>
</tr>
<tr>
<td>fear of positive evaluation (FPE) 439</td>
<td></td>
</tr>
<tr>
<td>major depressive disorder 205–7</td>
<td></td>
</tr>
<tr>
<td>developmental contextualism 183–4</td>
<td></td>
</tr>
<tr>
<td>diagnosis</td>
<td></td>
</tr>
<tr>
<td>differential diagnosis 279–80</td>
<td></td>
</tr>
<tr>
<td>interviews 282–4</td>
<td></td>
</tr>
<tr>
<td>discriminant validity 302</td>
<td></td>
</tr>
<tr>
<td>disqualification of positive social outcomes (DPSO) 438, 441–2, 448</td>
<td></td>
</tr>
<tr>
<td>diversity considerations 223–5, 240–1</td>
<td></td>
</tr>
<tr>
<td>assessment 231–3</td>
<td></td>
</tr>
<tr>
<td>case conceptualization 238–40</td>
<td></td>
</tr>
<tr>
<td>CBT 511–13</td>
<td></td>
</tr>
<tr>
<td>cultural variation in presentation influences on presentation 230–1</td>
<td></td>
</tr>
<tr>
<td>specific presentations 229–30</td>
<td></td>
</tr>
<tr>
<td>minority stress and SAD theories 225</td>
<td></td>
</tr>
<tr>
<td>linking models 228–9</td>
<td></td>
</tr>
<tr>
<td>minority stress models 225–8</td>
<td></td>
</tr>
<tr>
<td>treatment</td>
<td></td>
</tr>
<tr>
<td>cognitive behavioral therapy (CBT) 233–7</td>
<td></td>
</tr>
<tr>
<td>pharmacotherapy 237</td>
<td></td>
</tr>
<tr>
<td>single case CBT studies 237–8</td>
<td></td>
</tr>
<tr>
<td>dorsal anterior cingulate cortex (dACC) 160</td>
<td></td>
</tr>
<tr>
<td>dorsal medial prefrontal cortex (DMPFC) 397</td>
<td></td>
</tr>
<tr>
<td>dorsolateral prefrontal cortex (DLPFC) 397</td>
<td></td>
</tr>
<tr>
<td>Dot probe task 328, 330</td>
<td></td>
</tr>
<tr>
<td>downward arrow technique 505</td>
<td></td>
</tr>
<tr>
<td>dysthymic disorder 207–8</td>
<td></td>
</tr>
<tr>
<td>ecological momentary assessment (EMA) 112, 308</td>
<td></td>
</tr>
<tr>
<td>ego self-identity goals 44</td>
<td></td>
</tr>
<tr>
<td>electromyography (EMG) 351</td>
<td></td>
</tr>
<tr>
<td>embodiment 357</td>
<td></td>
</tr>
<tr>
<td>emotion regulation 31, 32, 188–9</td>
<td></td>
</tr>
<tr>
<td>emotion systems, functional analysis of 30–1</td>
<td></td>
</tr>
<tr>
<td>emotional reactivity 413</td>
<td></td>
</tr>
<tr>
<td>endogenous glucocorticoids 455–6</td>
<td></td>
</tr>
<tr>
<td>endophenotypes of SAD 400</td>
<td></td>
</tr>
<tr>
<td>brain-derived neurotrophic factor (BDNF) 401</td>
<td></td>
</tr>
<tr>
<td>oxytocin receptor (OXTR) gene 401</td>
<td></td>
</tr>
<tr>
<td>serotonin transporter (5-HTT) gene 400–1, 2</td>
<td></td>
</tr>
<tr>
<td>erythrophobia 101</td>
<td></td>
</tr>
<tr>
<td>escitalopram 526, 529</td>
<td></td>
</tr>
<tr>
<td>estradiol 462</td>
<td></td>
</tr>
<tr>
<td>endogenous release 463</td>
<td></td>
</tr>
<tr>
<td>exogenous administration 464–5</td>
<td></td>
</tr>
<tr>
<td>event reactivity 413</td>
<td></td>
</tr>
<tr>
<td>evolutionary models of SAD 16–17, 24, 46</td>
<td></td>
</tr>
<tr>
<td>competition and evolutionary change dynamics 31–2</td>
<td></td>
</tr>
<tr>
<td>resource competition, group living and social hierarchies 33</td>
<td></td>
</tr>
<tr>
<td>competition and social rank and subordination 33–6</td>
<td></td>
</tr>
<tr>
<td>low rank and positive evaluation 38–40</td>
<td></td>
</tr>
<tr>
<td>paranoia and SAD 37–8</td>
<td></td>
</tr>
<tr>
<td>self-blame and self-criticism 36–7</td>
<td></td>
</tr>
<tr>
<td>developing compassion 44–5</td>
<td></td>
</tr>
<tr>
<td>functional analysis of emotion systems 30–1</td>
<td></td>
</tr>
<tr>
<td>general evolutionary processes in SAD 24–5</td>
<td></td>
</tr>
<tr>
<td>old and new brain mechanisms 25</td>
<td></td>
</tr>
<tr>
<td>social mentalities 26–30</td>
<td></td>
</tr>
<tr>
<td>self-compassion 45–6</td>
<td></td>
</tr>
</tbody>
</table>
Index

evolutionary models of SAD (Continued)
social attractiveness and affiliative psychology 40–1
emotion regulation 42–3
shame 41–2
treatment implications 43–4
exogenous glucocorticoid administration 456–7
experiential avoidance 29
exploratory factor analysis (EFA) 302
exposure guidelines 507–8
exposure hierarchy 507
external shame 42
external validity 307
extroversion 58–9
facial mimicry 350–1
factorial discriminant validity 302
fear of negative evaluation (FNE) 433, 437
Fear of Negative Evaluation (FNE) scale 354, 377
fear of positive evaluation (FPE) 7, 433, 437–8, 450
clinical implications 447–9
cognitive–behavioral components 447
behavior 446–7
cognitions 441–2
emotions and arousal 442–5
future directions 449–50
theoretical overview
assessment of FPE 436
basic properties 435–6
distinctions 437–41
overall construct validity 436–7
positivity impairment 434
psycho-evolutionary considerations 434
fear of success 439–40
feared social situation types 250
fear of displaying physical signs of social anxiety 252–3
fear of offending others 253
performance fears 250–1
social interaction and observation fears 252
fearful temperament 92–3
fight–flight–freeze system (FFFS) 14–15, 91, 501
five-factor theory (FFT) of personality 116–18
fluoxetine 483, 484, 526, 528, 529
fluvoxamine 524, 529
friendship development models 163–5, 168–9
fusiform cortex 70–1
fuzzy-clustering method 55
gabapentin 527, 532, 534
gamma-aminobutyric acid (GABA) 458
gaze avoidance 446–7
generalized anxiety disorder (GAD) 171, 202–3
generalized social anxiety disorder (GSAD) 247–9
genetic factors in SAD 53
behavioral inhibition (BI) 135–6
family and twin evidence 54
future directions 60–1, 74–5
genetic association studies 56
behavioral inhibition (BI) and selective mutism 59–60
blushing 57
extroversion 58–9
neuroticism 57–8
shyness 57
social anxiety disorder 56–7
genetic linkage studies 54–6
genome-wide association studies (GWAS) 58, 59
glucocorticoids, endogenous 455–6
glucocorticoids, exogenous 456–7
gonadal hormones 461
endogenous release 462–3
exogenous administration 463–5
synthesis and sites of action 462
group cognitive behavioral therapy (GCBT) 171, 207
group living 33
guided net-bibliotherapy 573
heterogeneity in SAD 247, 261
diagnostic subtypes
comorbid avoidant personality disorder (APD) 249–50
generalized social anxiety disorder (GSAD) 247–9
Index

feared social situation types 250
performance fears 250–1
social interaction and observation fears 252
functioning, heterogeneity 255
demographic variables 256–7
symptom severity 255–6
personality considerations 253–4
understudied contexts and groups 257
Internet users 259–61
medical settings 257–8
veterans 258–9
variations in focus of social fears 252
fear of displaying physical signs of social anxiety 252–3
fear of offending others 253
high social anxiety (HSA) 323
future research 335–6
implicit associations 333–4
judgment biases 324–6
post-event processing (PEP) and memory 331–3
selective attention bias 326–7
conscious 329–31
unconscious 327–8
Hofmann model of SAD 9–10
hormones, gonadal 461
endogenous release 462–3
exogenous administration 463–5
synthesis and sites of action 462
hyperarousal 93, 94–6
hypervigilance 345, 357
hypothalamic–pituitary–adrenal (HPA) axis 160–1, 454–5, 458, 465
hypothalamic–pituitary–gonadal (HPG) axis 462, 465
hypothalamus 91
ideal self 122
immune function and SAD 75–6
impact message 163
implicit association test (IAT) 310, 333
impression management 167
insecure attachment 142, 188
insula 69–70
interference effect 329
internal shame 41–2
Internet-delivered treatments for SAD 571–2, 583
discussion 582–3
SAD and the Internet 572–3
effectiveness 580–1
effectiveness in real clinical settings 581
effects of treatment 575–7
guidance and support roles 578–9
long-term outcome studies 577–8
moderators of outcome 581–2
security issues 575
therapist identity 579–80
treatment programs 573–4
interoceptive exposure 500, 509
interpersonal circumplex theory 119–21
interpersonal distance 349–50
interpersonal functioning 255
interpersonal interactions and SAD 166
dysfunctional behavior as relational strategies 166–8
friendship development 168–9
intimate relationships 169–71
interpersonal model of SAD 15–16
interpersonal psychotherapy (IPT) 482–3
interpersonal transaction cycle 163
interpretation bias modification (IBM) programs 421
interpretation training 516
intimate relationships 169–71
isolation 449
James–Lange theory of emotion 73
judging audience 41
labeled praises 275
lesbian, gay, bisexual (LGB) individuals 225, 228, 232–3, 236
cognitive–behavioural therapy (CBT) 489
levetiracetam 527, 532–3
Liebowitz Social Anxiety Scale (LSAS) 284–5, 446, 522
life satisfaction 256
LOD scores 54–5
loneliness 160
looking glass self 40
major depressive disorder (MDD) 205–7, 279
metacognitive awareness 595
<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>synthesis, storage and site of action</td>
</tr>
<tr>
<td>vasopressin administration</td>
</tr>
<tr>
<td>stress response</td>
</tr>
<tr>
<td>endogenous glucocorticoids</td>
</tr>
<tr>
<td>exogenous glucocorticoid administration</td>
</tr>
<tr>
<td>neuropeptides, social</td>
</tr>
<tr>
<td>endogenous release</td>
</tr>
<tr>
<td>exogenous manipulation and release</td>
</tr>
<tr>
<td>oxytocin administration</td>
</tr>
<tr>
<td>synthesis, storage and site of action</td>
</tr>
<tr>
<td>vasopressin administration</td>
</tr>
</tbody>
</table>

| metacognitive therapy | 594–5 |
| mindfulness-based cognitive therapy (MBCT) | 481–2, 595–6 |
| mindfulness-based stress reduction (MBSR) | 481, 593–4 |
| neuroimaging studies | 485 |
| mindfulness-based therapies | 481–2, 590–2 |
| ACT for social anxiety | 598–601 |
| emergence | 592–3 |
| meditation-based programs |
| metacognitive therapy | 594–5 |
| mindfulness-based cognitive therapy (MBCT) | 595–6 |
| mindfulness-based stress reduction (MBSR) | 593–4 |
| modern behavior analytic approaches | 596–7 |
| acceptance and commitment therapy (ACT) | 597–8 |
| minorities see diversity considerations |
| minority stress theory | 223 |
| mirtazapine | 527, 531 |
| moclobemide | 523, 531, 534 |
| monoamine oxidase inhibitors (MAOIs) | 521, 530 |
| Moscovitch model of SAD | 10–11 |
| motivation enhancement therapy (MET) | 561–3 |
| motivational interviewing | 275–7, 487–8 |
| mutual influence | 163 |
| need to belong | 345–6 |
| nefazodone | 527, 531 |
| negative affect syndrome | 125 |
| negative feedback, preference for | 440–1 |
| neuroendocrinology of SAD | 454 |
| future directions | 465–6 |
| gonadal hormones | 461 |
| endogenous release | 462–3 |
| exogenous administration | 463–5 |
| synthesis and sites of action | 462 |
| social neuropeptides | 457–8 |
| endogenous release | 458–9 |
| exogenous manipulation and release | 459 |
| oxytocin administration | 459–60 |
| occupational functioning | 255–6 |
| olanzapine | 527, 533 |
| orbitofrontal cortex (OFC) | 72, 397 |
| ought self | 122 |
| over-identification | 449 |
| oxytocin administration | 459–60 |
| withdrawal behaviors | 459 |
| oxytocin receptor (OXTR) gene | 401 |
| panic disorder with/without agoraphobia | 136, 204 |
| paranoia and SAD | 37–8 |
| paraphrasing | 276 |
| parasympathetic anxiety | 94–6 |
| parental criticism | 142 |
| parental overprotectiveness | 142 |
| parent–child relationship | 187 |
| parenting practices | 191–2 |
| paroxetine | 524, 525, 528, 529, 534–5 |
| pathophysiology of SAD | 90 |
| cultural aspects | 101–4 |
| future directions | 104–5 |
| physiological aspects to etiology/maintenance of SAD | 97–9 |
| physiological correlates of anxiety | 90–2 |
| physiological correlates of fearful temperament | 92–3 |
Index

physiological correlates of SAD 93
blushing 96–7
hyperarousal, sympathetic and parasympathetic anxiety 94–6
physiology of SAD subtypes 99–101
peer relationships 192–4
performance fears 250–1
personal space 349–50
personality and SAD 112, 125–6
clinical implications 125
future directions 124–5
personality theories
common themes 123–4
five-factor theory (FFT) 116–18
interpersonal circumplex theory 119–21
self-regulation theory 121–3
trait–affect theory 118–19
treatment 112–16
personality considerations 253–4
personality disorders, assessing 280
pharmacotherapy 521–2, 539–40
children and adolescents 537
clinical approach
assessment 537–8
choice of treatment 538–9
monitoring and discontinuation of treatment 539
combination, augmentation and switching of treatments
medication 534–5
medications and psychotherapy 535–6
diversity considerations 237
meta-analyses 533–4
monotherapy
β-adrenergic antagonists 532
benzodiazepines 531–2
monoamine oxidase inhibitors (MAOIs) 530
other antidepressants 531
other medications 532–3
reversible inhibitors of monoamine oxidase A (RIMAs) 530–1
SSRIs and SNRIs 522–30
treating SAD with comorbid disorders 536
phenelzine 483, 523, 530, 534
physiologic reactivity 134
physiological arousal 445
positive affect stimulation and sustainment
(PASS) 422
Positive and Negative Affect Schedule (PANAS) 118–19, 311, 411
positivity impairment as a feature of SAD 409–11, 434
causal status of positive affect 419
attention bias modification (ABM) programs 420
cognitive modification training studies 420
interpretation bias modification (IBM) programs 421
longitudinal studies 419–20
implications and future directions 422
core features 421–2
treatment 422
reactivity to positive signals 412–13
attention 413
cognitive biases 415
event reactivity 416–17
interpretation and evaluation 414
memory 414–15
smiles 415–16
stimulus reactivity 413
regulation of positive emotions 417–19
scope 411–12
post-event processing (PEP) 7, 331–3, 501
posttraumatic stress disorder (PTSD) 139, 205
preference for negative feedback 440–1
prefrontal cortex (PFC) 71–2, 76–7
pregabalin 527, 532
preparedness 25
preventive intervention 142–7
pride 411–12
progressive muscle relaxation (PMR) 479
prosocial concepts 166
psychobiological models of SAD 16–17
quasi-behavioral measures 310
quetiapine 527, 533
Rapee–Heimberg model of SAD 5–7, 347
reflection 276
regulatory focus theory 122
Index

Reinforcement Sensitivity Theory (RST) 13–15
relational processes in SAD 159–60, 172
  circumplex models 162–3
  friendship development models 163–5
  interpersonal interactions 166
  dysfunctional behavior as relational strategies 166–8
  friendship development 168–9
  intimate relationships 169–71
  relational theories 162
  relationships 161–2
  risk-regulation models 165–6
  social bonds and human wellbeing 160–1
  underexplored areas 171–2
relational schema 15
relaxation techniques 480–1, 511
resource competition 33
response modification 418
reversible inhibitors of monoamine oxidase A (RIMAs) 521, 530–1
risk-regulation models 165–6
risperidone 533
self-blame 36–7
self-compassion 45–6
self-concealment 167
self-conscious emotions 159
self-construal 231
self-control theory 123
self-criticism 36–7
self-disclosure 276
self-judgment 449
self-kindness 449

self-presentation model of SAD 12–13
self-reappraisal 76–7
self-reference 76–7
self-regulation theory 121–3
self-report assessment 292–8, 312
  evaluating assessment tools 298
  reliability 299
  validity 299–303
future of self-report assessment 311
  multiple types of tools 311–12
  psychometric analyses 312
  practical guide to assessment selection 303–4
  assessment of related constructs 304
  assessments at different levels of the model 304–5
  sample measure analysis 305–6
  real problems, illusory problems and problematic solutions 306–7
  behavioral measures 309–10
  limits to self-report 307–8
  psychophysiological measures 310–11
  some solutions 308
  utility of interviews 308–9
  recommended self-report assessment tools 293–7
self-reported submissive behaviors 446
self-verification theory 440
serotonin transporter (5-HTT) gene 400–2
sertraline 484, 525, 526, 528, 529
sexual attractiveness 33–4
sexual orientation 223
shame 41–2
shyness 57
Shyness (program) 574
simulated exposure 509
situation modification 417
situation selection 417
situational exposure 509
social attention–holding power (SAHP) 26
social attractiveness 40–1
  emotion regulation 42–3
  shame 41–2
social behavior 352–4
Social Behavior and Anxious Appearance Rating Scale 352
social bonds 160–1
social comparisons 442
social hierarchies 33
Social Interaction Anxiety Scale (SIAS) 232, 305–6
social interaction fears 252
social isolation 76, 160
social mentality 27
social neuropeptides 457–8
endogenous release 458–9
exogenous manipulation and release 459
oxytocin administration 459–60
synthesis, storage and site of action 458
vasopressin administration 461
social neuroscience of SAD 67–8, 79–80
current research 69
brain imaging of socioemotional processing 69–72
physiological and behavioral data 72–3
summary 73–4
future research directions 74
genetics 74–5
immune function 75–6
insight from other disorders 79
limited scope of social stimuli 77–9
self-reference, self-reappraisal and social others 76–7
social isolation 76
scope 68–9
social others 76–7
Social Phobia and Anxiety Inventory (SPAI) 376–7
social rank 33–6
low rank and positive evaluation 38–40
paranoia and SAD 37–8
self-blame and self-criticism 36–7
social reprisal fears 442
social skills 352–4
social skills literature 366–7
future directions 382–3
problems
assessment measures 381–2
comparison groups 378–9
defining social skills 376
laboratory tasks 379–81
sample selection 376–8
studies 368–75
treating social anxiety by targeting social skills 382
social skills training (SST) 382, 479–80, 509–10
socially anxious individuals (SAIs) 344
biased processing and behavior 346–8
cognition and behavior 355–9
social devaluation behaviors 348
anxious behavior 354–5
avoidance during social interactions 348–9
behavioral and facial mimicry 350–1
interpersonal distance and personal space 349–50
social skills and social behavior 352–4
socially anxious temperament 111–12, 125–6
clinical implications 125
common themes among theories 123–4
future directions 124–5
personality 112
personality theories
five-factor theory (FFT) 116–18
interpersonal circumplex theory 119–21
self-regulation theory 121–3
trait–affect theory 118–19
personality, theory of 112–16
sociometer theory 12, 26, 159
SOFIE program 573
effects 575–6
therapist 579–80
Standards for Educational and Psychological Testing (SEPT) 298
reliability 299
internal consistency 299
test–retest reliability 299
validity 299–300
beyond nomological net 302–3
common method variance (CMV) 303
convergent and discriminant validity 302
definition of validity 300–1
factorial discriminant validity 302
startle reflex 36, 94
state anxiety 444–5
state-level positive and negative affect 443
status evaluation 35–6
Stopa model of SAD 11–12
stress response 454–5
endogenous glucocorticoids 455–6
exogenous glucocorticoid administration 456–7
striatum 70
structural equation modeling 168
Structured Clinical Interview for DSM-IV (SCID-IV) 283
Structured Clinical Interview for Social Anxiety Spectrum (SCI-SHY) 284
submissive behaviors 34
objectively assessed 446–7
self-reported 446
submissive caring 44
subordinate living 39–40
subordination 33–6
low rank and positive evaluation 38–40
paranoia and SAD 37–8
self-blame and self-criticism 36–7
substance abuse and SAD 549, 564
future directions 563
cognitive restructuring techniques 564
individual treatment 563
learning skills 563
mechanisms of poorer treatment outcomes 554
coping-motivated use 554
performance fears 554
socially motivated use 554–5
public health implications 552
rates 549–50
recommendations 559
assessment 559–60
diagnostic feedback 560–1
integrated treatment 561–3
temporal relations 551–2
treatment outcomes 552–3
anxiety and relapse 553
anxiety remains following treatment 553
poor treatment adherence 553
treatment populations 551
treatment strategies 555–6
integrated treatments 558–9
parallel treatments 556–8
subtypes of SAD 99–101
CBT outcomes 486
comorbid avoidant personality disorder (APD) 249–50
generalized social anxiety disorder (GSAD) 247–9
sympathetic activation 94–6
sympathetic–adrenal medullary (SAM) axis 91, 454–5
taijin kyofusho (TKS) 102, 229–30, 253, 281
taxometric analyses 114
testosterone 462, 465
endogenous release 462–3
exogenous administration 463–4
thought record 502–3
threat displays 345
threat-detection systems 346
tiagabine 533
tobacco use 213, 550
topiramate 533
trait–affect theory 118–19
trait-level positive and negative affect 442–3
transactional model 183–4
translational research 391, 402–3
behavioral genetics and endophenotypes of SAD 400
brain-derived neurotrophic factor (BDNF) 401
oxytocin receptor (OXTR) gene 401
serotonin transporter (5-HTT) gene 400–2
neuroimaging techniques 394–5
amygdala hyperreactivity 395–7
amygdala response before and after SAD treatment 398–9
frontal involvement in emotion regulation 397–8
treatment selection 399–400
role of cognitive enhancers 392
cortisol 393
D-cycloserine (DCS) 392–3
oxytocin 393–4
tranylcypromine 530
Index

unconditioned stimulus (US) 456
uncontrollable processing 333

unconditioned stimulus (US) 456
uncontrollable processing 333

valproic acid 533
vasopressin 458
administration 461
withdrawal behaviors 459
venlafaxine 526, 527, 528, 529
ventrolateral prefrontal cortex (VLPFC) 397
video feedback 478–9, 488, 510
virtual reality exposure therapy (VRET) 515
wellbeing 160–1
William’s syndrome (WS) 79
word–sentence association paradigm (WSAP) 421

valproic acid 533
vasopressin 458
administration 461
withdrawal behaviors 459
venlafaxine 526, 527, 528, 529
ventrolateral prefrontal cortex (VLPFC) 397
video feedback 478–9, 488, 510
virtual reality exposure therapy (VRET) 515
wellbeing 160–1
William’s syndrome (WS) 79
word–sentence association paradigm (WSAP) 421